Nonetheless, a recent study indicates that FASN inhibition is highly detrimental to the growth of prostate carcinoma cell lines, while it does not affect the oncogenic properties of pancreatic adenocarcinoma cells [50]. Here, FASN is linked to prostate carcinoma.